BR0212770A - Sais mandelato de derivados de tetrahidrofurano tetracìclico substituìdo - Google Patents

Sais mandelato de derivados de tetrahidrofurano tetracìclico substituìdo

Info

Publication number
BR0212770A
BR0212770A BR0212770-9A BR0212770A BR0212770A BR 0212770 A BR0212770 A BR 0212770A BR 0212770 A BR0212770 A BR 0212770A BR 0212770 A BR0212770 A BR 0212770A
Authority
BR
Brazil
Prior art keywords
mandelate
salts
mandelate salts
salts according
hydrogen
Prior art date
Application number
BR0212770-9A
Other languages
English (en)
Inventor
Bart Petrus Anna Maria Medaer
Sigrid Carl Maria Stokbroekx
Yves Georges Ruysschaert
Joannes Josephus Maria Willems
Johan Erwin Edmond Weerts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0212770A publication Critical patent/BR0212770A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

"SAIS MANDELATO DE DERIVADOS DE TETRAHIDROFURANO TETRACìCLICO SUBSTITUìDO". O objetivo da presente invenção é um novo sal mandelato de um derivado de tetrahidrofurano tetracíclico substituído de acordo com a Fórmula (I), as formas de N-óxido e as formas estereoquimicamente isoméricas do mesmo, em que R^ 1^ e R^ 2^ cada um independentemente é hidrogênio ou C~ 1~-C~ 6~-alquila e em que R^ 3^ e R^ 4^ cada um independentemente é hidrogênio ou halogênio. Nas definições anteriores, C~ 1~-C~ 6~-alquila define radicais hidrocarbonetos de cadeia reta e ramificada que têm desde 1 até 6 átomos de carbono tais como, por exemplo, metila, etila, propila, butila, 1-metil-propila, 1,1 dimetiletila, pentila ou hexila. O novo sal mandelato não é sensível à luz e é muito mais estável do que os sais da técnica anterior à temperatura ambiente, temperatura melhorada e a umidades relativamente altas e em meios aquosos. Também são divulgadas composições farmacêuticas que compreendem sais mandelato de acordo com a invenção, sais mandelato de acordo com a invenção para uso como um medicamento, um processo para a preparação dos sais mandelato de acordo com a invenção e o uso dos sais mandelato e de composições farmacêuticas que compreendem sais mandelato de acordo com a invenção para o tratamento ou para a prevenção de distúrbios do SNC, distúrbios cardiovasculares e distúrbios gastrointestinais.
BR0212770-9A 2001-11-09 2002-11-08 Sais mandelato de derivados de tetrahidrofurano tetracìclico substituìdo BR0212770A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204465 2001-11-09
PCT/EP2002/011136 WO2003040122A1 (en) 2001-11-09 2002-11-08 Novel mandelate salts of substituted tetracyclic tetrahydrofuran derivatives

Publications (1)

Publication Number Publication Date
BR0212770A true BR0212770A (pt) 2004-10-13

Family

ID=8181272

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212770-9A BR0212770A (pt) 2001-11-09 2002-11-08 Sais mandelato de derivados de tetrahidrofurano tetracìclico substituìdo

Country Status (25)

Country Link
US (1) US7317115B2 (pt)
EP (1) EP1446397B1 (pt)
JP (1) JP2005508988A (pt)
KR (1) KR100962325B1 (pt)
CN (1) CN1582282B (pt)
AR (1) AR037285A1 (pt)
AT (1) ATE299138T1 (pt)
AU (1) AU2002349327B2 (pt)
BR (1) BR0212770A (pt)
CA (1) CA2465043C (pt)
DE (1) DE60204982T2 (pt)
EA (1) EA006980B1 (pt)
ES (1) ES2244818T3 (pt)
HR (1) HRP20040395A2 (pt)
HU (1) HUP0402224A3 (pt)
IL (2) IL161866A0 (pt)
MX (1) MXPA04004365A (pt)
MY (1) MY128237A (pt)
NO (1) NO328548B1 (pt)
NZ (1) NZ531739A (pt)
PL (1) PL368456A1 (pt)
TW (1) TW200407117A (pt)
UA (1) UA79248C2 (pt)
WO (1) WO2003040122A1 (pt)
ZA (1) ZA200403454B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60203937T2 (de) * 2001-12-07 2006-05-11 Janssen Pharmaceutica N.V. Herstellung von trans-kondensierte 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivaten
WO2005013969A1 (en) * 2003-07-15 2005-02-17 Janssen Pharmaceutica N.V. Antipsychotic agent with socializing properties
RU2401257C2 (ru) 2004-12-07 2010-10-10 Янссен Фармацевтика Н.В. Новые замещенные тетрациклические производные тетрагидрофурана, пирролидина и тетрагидротиофена
MX2007009092A (es) 2005-01-27 2007-09-12 Janssen Pharmaceutica Nv Derivados de tetrahidrofurano tetraciclicos heterociclicos como inhibidores de 5ht2 en el tratamiento de trastornos del sistema nervioso central.
AU2006259020C1 (en) 2005-06-17 2012-01-19 Janssen Pharmaceutica N.V. Novel tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain
US8765223B2 (en) * 2008-05-08 2014-07-01 Air Products And Chemicals, Inc. Binary and ternary metal chalcogenide materials and method of making and using same
US8507040B2 (en) 2008-05-08 2013-08-13 Air Products And Chemicals, Inc. Binary and ternary metal chalcogenide materials and method of making and using same
US8962675B1 (en) * 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3644462A1 (de) * 1986-12-24 1988-07-07 Basf Ag Verfahren zur herstellung von 5h-dibenzo(a,d)cyclohepten-5-onen
JP2656720B2 (ja) * 1992-12-09 1997-09-24 武田薬品工業株式会社 光学活性アミノクマラン誘導体
ATE201680T1 (de) * 1994-03-16 2001-06-15 Cenes Ltd 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
DE69720709T2 (de) * 1996-04-12 2004-03-11 Janssen Pharmaceutica N.V. Substituierte tetracyclische tetrahydrofuranderivate
KR19990044257A (ko) 1996-05-20 1999-06-25 디르크 반테 생체이용율이 개선된 항진균성 조성물
UA52778C2 (uk) * 1997-10-10 2003-01-15 Янссен Фармацевтика Н.В. Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі
US6281247B1 (en) * 1998-03-03 2001-08-28 Novo Nordisk A/S Salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl)amide
HUP9904624A2 (hu) * 1999-12-17 2002-01-28 Sanofi-Synthelabo Szacharinszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és intermedierjeik
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist

Also Published As

Publication number Publication date
ZA200403454B (en) 2005-08-31
CN1582282A (zh) 2005-02-16
NO20041848L (no) 2004-05-05
DE60204982D1 (de) 2005-08-11
EP1446397A1 (en) 2004-08-18
ATE299138T1 (de) 2005-07-15
ES2244818T3 (es) 2005-12-16
NO328548B1 (no) 2010-03-15
HRP20040395A2 (en) 2005-04-30
UA79248C2 (en) 2007-06-11
IL161866A0 (en) 2005-11-20
AR037285A1 (es) 2004-11-03
EA006980B1 (ru) 2006-06-30
EP1446397B1 (en) 2005-07-06
IL161866A (en) 2010-04-29
US7317115B2 (en) 2008-01-08
MY128237A (en) 2007-01-31
PL368456A1 (en) 2005-03-21
AU2002349327B2 (en) 2008-10-23
KR100962325B1 (ko) 2010-06-11
MXPA04004365A (es) 2004-08-11
HUP0402224A2 (hu) 2005-02-28
HUP0402224A3 (en) 2007-05-29
TW200407117A (en) 2004-05-16
US20050085533A1 (en) 2005-04-21
KR20050044310A (ko) 2005-05-12
CA2465043C (en) 2011-02-15
JP2005508988A (ja) 2005-04-07
WO2003040122A1 (en) 2003-05-15
CA2465043A1 (en) 2003-05-15
EA200400656A1 (ru) 2004-10-28
CN1582282B (zh) 2012-06-06
NZ531739A (en) 2005-02-25
DE60204982T2 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
BRPI0606319A2 (pt) compostos farmacêuticos
BR0210384A (pt) Heteroarilas multicìclicas substituìdas por quinuclidinas para o tratamento de doença
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
BRPI0407543A (pt) derivados de piperidina-benzenossulfonamida
BRPI0816767B8 (pt) composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
BRPI0515524A (pt) compostos quìmicos
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BR0206670A (pt) Compostos halogenados que exibem agonismo para receptor de trombopoietina
BRPI0515412A (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
PT1254138E (pt) Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
BR0307687A (pt) Composições cosméticas tópicas
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
CL2004000769A1 (es) Compuestos derivados del acido [2-(8,9-dioxo-2,6-diazabiciclo [5,2,o]non-1-(7)-en-2-il) alquil]fosfonico, antagonistas del receptor n-metil-d-aspartato (nmda); procedimiento de preparacion; composicion farmaceutica; y su uso para tratar desordenes va
BR9809648A (pt) Derivados de piperazinil-benzil-tetrazol antiinflamatórios e intermediários dos mesmos
BR0210733A (pt) Derivados de piperidina de utilidade úteis como moduladores da atividade do receptor de quimocina
DK1412354T3 (da) Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter
BRPI0506718A (pt) compostos, processo de preparação dos mesmos, e, composição farmacêutica ou cosmética
BR0212770A (pt) Sais mandelato de derivados de tetrahidrofurano tetracìclico substituìdo
BR0310032A (pt) Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos
BRPI0504780A (pt) compostos de benzotiadiazina, processo para sua preparação e composições farmacêuticas contendo os mesmos
ATE342261T1 (de) Pyranderivate als inhibitoren von ace und nep
CY1105550T1 (el) Μεμνο-πεπτιδια, μια διαδικασια για την παρασκευη και τη χρηση τους
BR9907100A (pt) Pentassacarìdeos, processo para a preparação dos mesmos e composições farmacêuticas que contêm os mesmos
BRPI0403028A (pt) Compostos heterocìclicos de oxima, processo para sua preparação e composições farmacêuticas contendo os mesmos
BR112014013719A2 (pt) compostos inibidores da lipogênese

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 307/93, A61K 31/343, A61P 25/18

Ipc: C07D 307/93 (2011.01), A61K 31/343 (2011.01), A61P

B25C Requirement related to requested transfer of rights

Owner name: JANSEN PHARMACEUTICA N.V. (BE)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020120000065/RJ DE 02/01/2012, E NECESSARIO COMPLEMENTAR A GUIA RELATIVA A CESSAO, BEM COMO RECOLHER A GUIA REFERENTE A ESTA EXIGENCIA.

B25A Requested transfer of rights approved

Owner name: ELANCO ANIMAL HEALTH IRELAND LIMITED (IE)

Free format text: TRANSFERIDO DE: JANSEN PHARMACEUTICA N.V.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.